Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex

Objective . Amyotrophic lateral sclerosis/parkinsonism-dementia complex is classified as one of the tauopathies. Methods . The total tau, phosphorylated tau, and amyloid β 42 levels were assayed in cerebrospinal fluid from patients with Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex ( n = 12), Alzheimer's disease ( n = 9), Parkinson's disease ( n = 9), amyotrophic lateral sclerosis ( n = 11), and controls ( n = 5) using specific enzyme-linked immunosorbent assay methods. Results . Total tau and phosphorylated tau did not increase and amyloid β 42 was relatively reduced in Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. Relatively reduced amyloid β 42 might discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from amyotrophic lateral sclerosis and Parkinson's disease, and the ratios of phosphorylated-tau to amyloid β 42 could discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer's disease. Conclusions . Cerebrospinal fluid analysis may be useful to differentiate amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease.